Equities

Roivant Sciences Ltd

Roivant Sciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)11.87
  • Today's Change0.11 / 0.94%
  • Shares traded3.00m
  • 1 Year change+32.18%
  • Beta1.2274
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments6,5361,6772,060
Total Receivables, Net8333--
Total Inventory352.76--
Prepaid expenses5561--
Other current assets, total232586
Total current assets6,7321,7992,147
Property, plant & equipment, net669287
Goodwill, net------
Intangibles, net138145--
Long term investments248304326
Note receivable - long term------
Other long term assets394916
Total assets7,2222,3902,585
LIABILITIES
Accounts payable533835
Accrued expenses185179139
Notes payable/short-term debt000
Current portion long-term debt/capital leases1243--
Other current liabilities, total161311
Total current liabilities267272184
Total long term debt431379210
Total debt443422210
Deferred income tax------
Minority interest480450404
Other liabilities, total77130129
Total liabilities1,2541,232928
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital5,3964,9334,422
Retained earnings (accumulated deficit)576(3773)(2764)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(4.08)(2.62)(0.95)
Total equity5,9691,1581,657
Total liabilities & shareholders' equity7,2222,3902,585
Total common shares outstanding807760695
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.